Zhu Yixiang, Wang Zhijie
CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing 100021, China.
Zhongguo Fei Ai Za Zhi. 2022 Jul 20;25(7):468-476. doi: 10.3779/j.issn.1009-3419.2022.102.22.
Antibody drug conjugates (ADCs) are a novel class of anti-cancer drugs, which combined the specificity of monoclonal antibodies with the cytotoxic palyload via the linkers. Many ADCs have not only verified impressive activity in a variety of cancers, including breast cancer and hematological system tumors, but also in lung cancer. The aim of this study was to provide informations for practice by summarizing the mechanism of action, clinical application and problems and challenges of ADCs. .
抗体药物偶联物（ADCs）是一类新型抗癌药物，它通过连接子将单克隆抗体的特异性与细胞毒性载荷结合在一起。许多抗体药物偶联物不仅在包括乳腺癌和血液系统肿瘤在内的多种癌症中展现出了令人瞩目的活性，在肺癌中亦是如此。本研究的目的是通过总结抗体药物偶联物的作用机制、临床应用以及问题与挑战，为实际应用提供信息。
